Bausch + Lomb
Novartis Divests Xiidra and Other Ophthalmology Assets to Bausch + Lomb for $2.5 Billion
SG Tylor
Source – Novartis In a strategic move to concentrate on its core areas, Novartis has decided to transfer the dry ...
Source – Novartis In a strategic move to concentrate on its core areas, Novartis has decided to transfer the dry ...